Attached files

file filename
EX-10.B - AMENDMENT AND WAIVER TO REVOLVING CREDIT FACILITY DATED JULY 30, 2012 - BRISTOL MYERS SQUIBB COq22020exhibit10b.htm
EX-32.B - EXHIBIT 32.B - BRISTOL MYERS SQUIBB CObmyex32b20200630.htm
EX-31.B - EXHIBIT 31.B - BRISTOL MYERS SQUIBB CObmyex31b20200630.htm
EX-31.A - EXHIBIT 31.A - BRISTOL MYERS SQUIBB CObmyex31a20200630.htm
EX-10.A - AMENDMENT AND WAIVER TO REVOLVING CREDIT FACILITY DATED SEPTEMBER 29, 2011 - BRISTOL MYERS SQUIBB COq22020exhibit10a.htm
10-Q - 10-Q - BRISTOL MYERS SQUIBB CObmy-20200630.htm

EXHIBIT 32a
Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the "Report"), as filed with the Securities and Exchange Commission on August 6, 2020, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.

 
/s/ Giovanni Caforio, M.D.
Giovanni Caforio, M.D.
Chairman of the Board and Chief Executive Officer
August 6, 2020
 

This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Report. A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.